The Cancer Imaging Core serves ACC investigators with cancer-related clinical trials and translational research that involve imaging biomarkers and/or imaging-related endpoints. The overarching goals of the Core are to facilitate and support the use of high quality, advanced imaging modalities in clinical trials by providing easily accessed, reliable, reproducible, timely and validated imaging data and results in a timely and cost- effective manner. In addition to scientific imaging consultation, the Core provides protocol development services, standardized data acquisition methods for cancer imaging trials, and expert image response assessment analyses. The Core supports investigator access to a variety of cancer imaging methods, both standard clinical imaging studies and novel cancer imaging methods developed by Penn investigators, e.g., cancer imaging biomarker methods. The Core's objectives are to: 1) provide high quality consistent image acquisition processes and image analysis for cancer clinical trials involving imaging endpoints; 2) assist with protocol development, submission and activation of cancer clinical trials that involve imaging modalities; 3) provide scientific consultation to clinical investigators on the most appropriate cancer imaging methods to meet scientific needs; and 4) direct investigators to the appropriate choice of both standard and advanced imaging methodologies in ACC clinical investigations. Users and usage has steadily increased over the current project period, and seven of 11 ACC Programs are actively using the Core services in their scientific studies. The Core's ability to provide cost-effective, consistent, and timely quantitative image response assessment is made possible through new web-based tools. Recent changes include: 1) recruitment of an experienced new Co- Leader, Dr. David Mankoff; 2) expanded and more highly automated services for imaging response assessment and support for advanced imaging methods; 3) expanded capabilities in PET and molecular imaging, and 4) recruitment of seasoned Core staff with experience in cancer imaging core administration and imaging-related regulatory matters. Through its support of both standard imaging in cancer clinical trials and advanced imaging for ACC clinical trials, the Core is poised to lead the ACC into the next generation of clinical and translational research studies guided by quantitative cancer imaging. The current yearly rate of imaging response assessment is over 800 studies per year, involving 57 trials, of which 46 were initiated in the current year. A total of 120 new protocols and 31 different investigators, all of whom are ACC members, used the Core in the reporting period (10/01/13-9/30/14). CCSG support represents 33% of the proposed Core budget with the remaining funding coming from charge backs and other grants/contracts. Additional Institutional support is provided in the form of funding for the development of advanced imaging and image analysis methods.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Career Development (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pennsylvania
United States
Zip Code
Jang, Jeong Hoon; Manatunga, Amita K; Taylor, Andrew T et al. (2018) Overall indices for assessing agreement among multiple raters. Stat Med 37:4200-4215
Garfall, Alfred L; Stadtmauer, Edward A; Hwang, Wei-Ting et al. (2018) Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight 3:
Romero, Sally A D; Brown, Justin C; Bauml, Joshua M et al. (2018) Barriers to physical activity: a study of academic and community cancer survivors with pain. J Cancer Surviv 12:744-752
Scheel, John R; Kim, Eunhee; Partridge, Savannah C et al. (2018) MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial. AJR Am J Roentgenol 210:1376-1385
Li, Jinyang; Byrne, Katelyn T; Yan, Fangxue et al. (2018) Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy. Immunity 49:178-193.e7
Hinderer, Christian; Katz, Nathan; Buza, Elizabeth L et al. (2018) Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN. Hum Gene Ther 29:285-298
Hordeaux, Juliette; Wang, Qiang; Katz, Nathan et al. (2018) The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL/6J Mice. Mol Ther 26:664-668
Raghunathan, Nirupa Jaya; Korenstein, Deborah; Li, Qing S et al. (2018) Determinants of mobile technology use and smartphone application interest in cancer patients. Cancer Med 7:5812-5819
Torre, Eduardo; Dueck, Hannah; Shaffer, Sydney et al. (2018) Rare Cell Detection by Single-Cell RNA Sequencing as Guided by Single-Molecule RNA FISH. Cell Syst 6:171-179.e5
Echevarría-Vargas, Ileabett M; Reyes-Uribe, Patricia I; Guterres, Adam N et al. (2018) Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. EMBO Mol Med 10:

Showing the most recent 10 out of 1047 publications